Home Antibody All anti-CD9 antibodies
Anti-CD9 Antibody eBioSN4 (SN4 C3-3A2)
|eBioSN4 (SN4 C3-3A2)
||0.5-1mg/ml (lot dependent)
||Flow, IHC, IP
|Aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer|
|Homo sapiens CD9 molecule (CD9)|
|BTCC-1; DRAP-27; MIC3; MRP-1; TSPAN-29; TSPAN29|
Entrez Gene 928 Human
|The eBioSN4 monoclonal antibody reacts with human CD9. CD9 is a 24 kDa member of the tetraspanin family, whose members are characterized by the presence of 4 hydrophobic transmembrane domains. CD9 is expressed in platelets, eosinophils, basophils, pre-B cells, activated T cells and neural cell lines. Furthermore, CD9 expression has been associated with a malignant phenotype, including expression on 90% of non T cell acute lymphoblastic leukemia cells and on 50% of chronic lymphocytic and acute myeloblastic leukemias. In platelets, CD9 is expressed in α-granules and through association with the integrin αIIb/βIII plays a role in platelet aggregation, as demonstrated by the use of anti-human CD9 antibodies. CD9 has also been shown to induce the aggregation of pre-B cell lines, and the adhesion and migration of pre-B cells and Schwann cells. Additionally, it has been demonstrated that CD9 is able to provide a co-stimulatory signal for T cells independently of CD28, in the absence of antigen-presenting cells. Binding of the eBioSN4 monoclonal antibody partially cross-blocks binding of another anti-human CD9 monoclonal antibody, MM2/57.|
|ES Cell Differentiation/IPSTransmembraneAdult stem cellsEmbryonic stem cellsDruggable Genome Hematopoietic cell lineage|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Staining of normal human peripheral blood cells with 0.25 ug of Mouse IgG11 K Isotype Control Purified (open histogram) or 0.25 ug of Anti-Human CD9 Purified (filled histogram) followed by Anti-Mouse IgG FITC . Total viable cells were used for analysis.